Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1967143 | 0.79 | GRIN2B (0.63) | SIGMAR1HTR2AGRIN2B | |
| SCHEMBL6246604 | 0.79 | SIGMAR1 (0.68) | SIGMAR1HRH3BCHECYP1A2CYP2A6 | |
| Hydrochloric Acid SCHEMBL7211179 | 0.78 | SIGMAR1 (0.66) | SIGMAR1HRH3BCHECYP1A2CYP2A6 | |
| SCHEMBL1970890 | 0.77 | CHIT1 (0.47) | SIGMAR1SLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL7352234 | 0.76 | SIGMAR1 (1.00) | SIGMAR1CYP1A2 | |
| SCHEMBL1970244 | 0.75 | TAAR1 (0.49) | SLC6A2SLC6A4SLC6A3HTR2AHRH3 | |
| SCHEMBL1965728 | 0.75 | AOC3 (0.63) | SIGMAR1HRH3 | |
| SCHEMBL27837194 | 0.74 | TAAR1 (0.65) | SIGMAR1HTR2AGRIN2B | |
| SCHEMBL25833470 | 0.74 | TAAR1 (0.65) | SIGMAR1HTR2AGRIN2B | |
| SCHEMBL1967611 | 0.74 | CHIA (0.54) | SIGMAR1HTR2AHRH3CYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010044054-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | SIGMAR1 108/4885SLC6A2 430/4885SLC6A4 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.